{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:19:21Z","timestamp":1791429561739,"version":"4.3.3"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamacardio.2020.2413","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T11:32:04Z","timestamp":1594207924000},"page":"1136","source":"Crossref","is-referenced-by-count":120,"title":["Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease"],"prefix":"10.1001","volume":"5","author":[{"given":"Rishi","family":"Puri","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit J.","family":"Arsenault","sequence":"additional","affiliation":[{"name":"Qu\u00e9bec Heart & Lung Institute, Universit\u00e9 de Laval, Qu\u00e9bec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"St John","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Riesmeyer","sequence":"additional","affiliation":[{"name":"Eli Lilly, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ruotolo","sequence":"additional","affiliation":[{"name":"Eli Lilly, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"McErlean","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"MonashHeart, Department of Cardiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"hoi200041r1","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease.","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi200041r2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"7","key":"hoi200041r3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction.","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"10057","key":"hoi200041r4","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"hoi200041r5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis.","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"hoi200041r6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis.","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"12","key":"hoi200041r7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"hoi200041r8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi200041r9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events.","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi200041r10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans.","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"hoi200041r11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jacl.2017.12.004","article-title":"Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: the Ioannina Study.","volume":"12","author":"Naka","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"20","key":"hoi200041r12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease.","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi200041r13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10155","key":"hoi200041r14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"hoi200041r15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003012","article-title":"Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS).","volume":"5","author":"Afshar","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"hoi200041r16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1006\/cyto.2001.0974","article-title":"C-reactive protein levels are influenced by common IL-1 gene variations.","volume":"17","author":"Berger","year":"2002","journal-title":"Cytokine"},{"issue":"1","key":"hoi200041r17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1161\/01.ATV.0000150039.60906.02","article-title":"Polymorphisms of the interleukin-1\u00df gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro.","volume":"25","author":"Iacoviello","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"hoi200041r18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00439-008-0488-6","article-title":"IL1B gene promoter haplotype pairs predict clinical levels of interleukin-1\u00df and C-reactive protein.","volume":"123","author":"Rogus","year":"2008","journal-title":"Hum Genet"},{"key":"hoi200041r19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN.","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"issue":"5","key":"hoi200041r20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2768166\/jamacardiology_puri_2020_oi_200041_1602688131.78491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:01:27Z","timestamp":1603278087000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2768166"}},"subtitle":["A Prespecified Secondary Analysis of the ACCELERATE Trial"],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2020.2413","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}